Table 2

Association of categorical baseline systolic blood pressure with outcomes

	Subgroup	Clopidogrel plus aspirin (N=1502)	Aspirin alone (N=1413)	Treatment effect metric	Unadjusted		Adjusted		P_int value
	Subgroup	Clopidogrel plus aspirin (N=1502)	Aspirin alone (N=1413)	Treatment effect metric	Treatment difference (95% CI)	P value	Treatment difference (95% CI)	P value	P_int value
Primary outcome
END at 7 days*	SBP<140 mm Hg	17/496 (3.4)	19/454 (4.2)	RD†	−0.8 (−3.2 to 1.7)	0.54	−0.8 (−3.2 to 1.7)	0.54	0.50
END at 7 days*	SBP≥140 mm Hg	55/1006 (5.5)	76/959 (7.9)	RD†	−2.5 (−4.7 to −0.2)	0.03	−2.5 (−4.1 to −1.0)	<0.01	0.50
Secondary outcomes
mRS 0–1 at 90 days‡	SBP<140 mm Hg	395/489 (80.8)	346/441 (78.5)	RD†	2.3 (−2.9 to 7.5)	0.38	2.3 (−2.9 to 7.5)	0.38	0.90
mRS 0–1 at 90 days‡	SBP≥140 mm Hg	735/981 (74.9)	669/920 (72.7)	RD†	2.2 (−1.7 to 6.2)	0.27	2.2 (−0.6 to 5.0)	0.12	0.90
mRS at 90 days‡	SBP<140 mm Hg	NA	NA	OR§	1.07 (0.84 to 1.36)	0.59	1.07 (0.84 to 1.36)	0.59	0.96
mRS at 90 days‡	SBP≥140 mm Hg	NA	NA	OR§	1.10 (0.93 to 1.29)	0.28	1.09 (0.97 to 1.23)	0.14	0.96
Change in NIHSS at 14 day¶	SBP<140 mm Hg	−0.69 (−1.25 to −0.34)	−0.65 (−1.61 to −0.34)	GMR†	0.02 (−0.57 to 0.59)	0.96	−0.15 (−0.72 to 0.42)	0.60	0.98
Change in NIHSS at 14 day¶	SBP≥140 mm Hg	−0.51 (−0.92 to −0.22)	−0.51 (-0.92 to −0.22)	GMR†	0.32 (−0.28 to 0.91)	0.29	0.32 (−0.09 to 0.73)	0.13	0.98
New stroke within 90 days**	SBP<140 mmHg	3/489 (0.6)	3/441 (0.7)	HR††	0.90 (0.18 to 4.47)	0.90	0.90 (0.18 to 4.47)	0.90	0.74
New stroke within 90 days**	SBP≥140 mm Hg	9/981 (0.9)	10/920 (1.1)	HR††	0.85 (0.34 to 2.08)	0.71	0.82 (0.33 to 2.04)	0.65	0.74
Other vascular events or death within 90 days	SBP<140 mm Hg	6/489 (1.2)	2/441 (0.5)	HR††	2.72 (0.55 to 13.47)	0.22	2.72 (0.55 to 13.47)	0.22	0.39
Other vascular events or death within 90 days	SBP≥140 mm Hg	10/981 (1.0)	10/920 (1.1)	HR††	0.94 (0.39 to 2.25)	0.89	0.93 (0.39 to 2.24)	0.87	0.39
Safety outcomes
Any bleeding events	SBP<140 mm Hg	6/496 (1.2)	5/454 (1.1)	RD†	0.1 (−1.3 to 1.5)	0.88	0.1 (−1.3 to 1.5)	0.88	0.65
Any bleeding events	SBP≥140 mm Hg	4/1006 (0.4)	9/959 (0.9)	RD†	−0.5 (−1.3 to 0.2)	0.14	−0.5 (−1.1 to 0.0)	0.05	0.65
Intracranial haemorrhage	SBP<140 mm Hg	1/496 (0.2)	1/454 (0.2)	RD†	0.0 (−0.6 to 0.6)	0.95	0.0 (−0.6 to 0.6)	0.95	0.99
Intracranial haemorrhage	SBP≥140 mm Hg	0/1006 (0.0)	1/959 (0.1)	RD†	−0.1 (−0.3 to 0.1)	0.31	−0.1	0.14	0.99

The data were shown with median (IQR) for continuous characteristic or frequency (percentages) for categorical characteristic.
*END was defined as an increase between baseline and 7 days of ≥2 on the NIHSS score, but not as result of cerebral haemorrhage.18
†Calculated using the generalised liner model.
‡Scores on the mRS of functional disability range from 0 (no symptoms) to 6 (death).
§A shift measures of function according to the full range of scores on the mRS at 90 days was analysed by ordinal logistic regression.
¶Patients with NIHSS scores of 4–10 were eligible for this study; NIHSS scores range from 0 to 42, with higher scores indicating more severe neurological deficit. The log (NIHSS+1) was analysed using generalised linear model.
**New stroke included ischaemic stroke and haemorrhagic stroke.
††Calculated using the Cox regression model.
END, early neurological deterioration; GMR, geometric mean ratio; mRS, modified Rankin Scale; NA, not applicable; NIHSS, National Institute of Health Stroke Scale; RD, risk difference; SBP, systolic blood pressure.